Navigation Links
GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
Date:12/6/2010

ATLANTA, Dec. 6, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), announced today the expansion of the Phase 2a clinical trial testing of its HIV/AIDS vaccine products. The expanded Phase 2a trial will test the administration of three doses of the recombinant poxvirus vaccine MVA62B without the use of the recombinant DNA-vectored vaccine, which was used to prime immune responses in the first part of this trial. At the completion of the trial, 150 participants will have received the vaccine products using two DNA inoculations followed by two MVA inoculations, 75 participants will have received the vaccine using three MVA inoculations and 75 participants will have received placebo. Enrollment into the expanded Phase 2a trial opened December 6th.

GeoVax is developing two vaccine components: a recombinant DNA-vectored vaccine and a recombinant MVA-vectored vaccine. Both produce non-infectious virus-like particles in the body of a vaccine recipient. These non-infectious particles are designed to "train" the immune system of the vaccinated person to recognize HIV should the vaccinated person be exposed to the real virus. Both the DNA and MVA vaccines induce humoral (antibody) and cellular (cytotoxic T cell) responses. Antibodies have the potential to block virus before it infects cells. The cytotoxic T cells have the potential to recognize and kill virus-infected cells. The vaccine is designed to control clade B HIV infections. Clade B HIV is found in North, Central and parts of South America, Western Europe, Australia and Japan.

"I like the simplicity of using the MVA-vectored vaccine alone because it is a regimen that could easily be taken forward for the world. The data from our Phase 1 clinical trial and recent preclinical data obtained using a non-human primate model support the use of this simplified vaccine regimen," said Harriet Robinson,
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
7. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
10. GeoVax Secures $10 Million Financing Commitment
11. GeoVax Reports Progress on Its AIDS Vaccine Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Fla. , July 11, 2014  Rock Creek ... biotechnology company, today announced that the Food and Drug ... will provide comments on RCP,s Investigational New Drug ("IND") ... clinical trial in the US. Dr. ... agency,s review and comments on our IND. When we ...
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... SCHAUMBURG, Ill. , Jan. 19 ... pharmaceutical company, today announced that it has launched ... per 10 mL and 90 mg per 10 mL.  Pamidronate disodium ... Aredia®, is a bone resorption inhibitor.  The 2008 ...
... , FRANKLIN LAKES, N.J. , Jan. ... MHS ) are scheduled to present at the following investor conferences: , ... the Jeffries 2010 Global Healthcare Services Conference on Monday, January 25, ... hotel in New York ; , David B. Snow Jr. ...
Cached Medicine Technology:Sagent Pharmaceuticals Launches Pamidronate Disodium Injection 2Medco to Present at Upcoming Investor Conferences 2
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... Sean Francis, owner of the Kawartha Lakes Fit ... his clients. He’s also known for his support of local non-profits ... to combine the two and is excited to announce that his ... and Girls Club. , The funds are the result of Francis’ ... Francis sent out emails and asked his clients to put out ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... 2014 Utah Valley Entrepreneurial Forum Top ... awards being bestowed to companies in revenue, and pre-revenue ... community with recognition for new ideas as well as ... revenue. , 25 Under 5 highlights outstanding Utah entrepreneurs ... under 5 years old. Award recipients were recognized at ...
(Date:7/12/2014)... 2014 Restore My Vision Today is ... Pearson, a couple boasting very impressive credentials on the ... Vision Today as a way to help consumers do ... in their respective patients’ treatments . , ... “secret” trove of pertinent information relevant to eye care ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... Susan G. Komen for the Cure(R) Advocacy Alliance applauds ... Kay Bailey Hutchison (R-TX) to reignite the war on ... Cancer ALERT ( A ccess to L ife-saving ... T reatment) Act. (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO )"It,s ...
... Hospital in Houston has agreed to pay the ... it defrauded the federal Medicare program, the Justice ... improperly increased charges to Medicare patients in order ... addition to its standard payment system, Medicare pays ...
... of government strategy to tackle issue , , THURSDAY, ... rivers were found to be tainted with traces of ... from the U.S. Environmental Protection Agency and Baylor University. ... two types of antidepressants were among the seven types ...
... KINGSTON, R.I. March 26, 2009 Two University of ... is regulated by reactive oxygen species (ROS) -- a type ... this protein normally behaves in human cells and may help ... student David J. Kemble and Professor Gongqin Sun in the ...
... 25% annually, according to Millennium Research GroupWALTHAM, Mass., ... (MRG,s) US Markets for Large-Joint Reconstructive Implants ... fastest-growing segment of the large-joint reconstructive implant market ... rate of over 25%. Hip resurfacing is ...
... March 26 /PRNewswire-USNewswire/ -- The U.S. ... today that 10,000 women have received surgery for ... a devastating vaginal injury affecting millions of women ... most of those with the condition lack access ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Applauds Senators Kennedy, Hutchison for Bipartisan Cancer Alert Act 2Health News:Houston's Methodist Hospital to Pay U.S. More Than $9 Million to Resolve Allegations of Overcharging Medicare 2Health News:Fish in U.S. Rivers Tainted With Common Medications 2Health News:URI scientists reveal mechanism that regulates cancer-causing gene 2Health News:Hip Resurfacing Championed as a Bone-Preserving Alternative to Total Hip Replacement 2Health News:Hip Resurfacing Championed as a Bone-Preserving Alternative to Total Hip Replacement 3Health News:Major Milestone Reached in Global Maternal Health 2
...
... The QuickLink™ Delivery System ... device designed to assemble ... SourceLink Connectors into seed ... and with variable seed ...
Stylish yet conservative, these classics are reliable, comfortable and durable....
Inquire...
Medicine Products: